Published in Int J Cell Cloning on July 01, 1988
Retracted Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest (1989) 0.99
Interleukin-2 and interferon-gamma recruit different subsets of human peripheral blood monocytes to secrete interleukin-1 beta and tumour necrosis factor-alpha. Clin Exp Immunol (1989) 0.86
Clonal analysis of CD4+/CD8+ T cells in a patient with aplastic anemia. J Clin Invest (1991) 0.82
Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell (1997) 7.47
SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J (2001) 4.32
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol (2000) 3.24
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A (1985) 3.02
Retracted Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med (1995) 2.97
Quantal release of serotonin. Neuron (2000) 2.56
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood (1996) 2.08
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count. Br J Dermatol (1998) 2.08
Mortality study of Canadian male farm operators: non-Hodgkin's lymphoma mortality and agricultural practices in Saskatchewan. J Natl Cancer Inst (1990) 2.00
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood (1994) 1.95
Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol (1985) 1.86
Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood (1992) 1.81
High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood (1989) 1.64
Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood (1997) 1.61
A cell-free system for regulated exocytosis in PC12 cells. J Cell Biol (2000) 1.60
Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. J Immunol (1984) 1.54
Granulocyte/macrophage colony-stimulating factor induces interleukin 1 production by human polymorphonuclear neutrophils. J Immunol (1988) 1.51
Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med (1982) 1.50
Screening for total cholesterol. Do the National Cholesterol Education Program's recommendations detect individuals at high risk of coronary heart disease? Circulation (1991) 1.45
Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer (1997) 1.41
Immunoisolation of GABA-specific synaptic vesicles defines a functionally distinct subset of synaptic vesicles. J Neurosci (2000) 1.40
Fluorescence nanoscopy with optical sectioning by two-photon induced molecular switching using continuous-wave lasers. Chemphyschem (2008) 1.39
An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. Bone Marrow Transplant (1996) 1.38
Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med (1985) 1.37
Retracted Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by human polymorphonuclear leukocytes. J Clin Invest (1989) 1.37
Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood (1989) 1.33
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer (2000) 1.32
Tumor necrosis factor (TNF)-alpha but not TNF-beta induces secretion of colony stimulating factor for macrophages (CSF-1) by human monocytes. Blood (1987) 1.31
IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett (1996) 1.29
Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs (1995) 1.29
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer (1996) 1.26
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. J Immunol (1985) 1.23
Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother (2000) 1.22
T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophages. Clin Immunol Immunopathol (1987) 1.19
Endoscopic sphincterotomy: follow-up evaluation of effects on the sphincter of Oddi. Gastroenterology (1984) 1.19
OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells. J Immunol (1983) 1.19
Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood (1980) 1.18
BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol (1996) 1.17
Picometer-scale electronic control of molecular dynamics inside a single molecule. Science (2005) 1.17
Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res (1990) 1.16
In vivo mechanical properties of leukocytes during adhesion to venular endothelium. Biorheology (1991) 1.16
A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes (1996) 1.16
Maternal levels of pregnancy-specific beta 1-glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome. Hum Genet (1988) 1.15
Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest (1985) 1.15
Pluripoietin alpha: a second human hematopoietic colony-stimulating factor produced by the human bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A (1986) 1.14
Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther (1999) 1.13
Production and regulation of interleukin-2 in human lymphoblastic leukemias studied with T-cell monoclonal antibodies. Blood (1983) 1.11
The SNARE Vti1a-beta is localized to small synaptic vesicles and participates in a novel SNARE complex. J Neurosci (2000) 1.09
Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. Immunobiology (1986) 1.09
N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood (1990) 1.07
Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2. Cell Immunol (1984) 1.07
Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood (1996) 1.07
Immunologic effects of interleukin 2 in primary immunodeficiency diseases. J Immunol (1983) 1.06
Correlation between physical performance and fatigue in cancer patients. Ann Oncol (1997) 1.05
Autologous and allogeneic mixed-lymphocyte responses following thermal injury in man: the immunomodulatory effects of interleukin 1, interleukin 2, and a prostaglandin inhibitor, WY-18251. Clin Immunol Immunopathol (1984) 1.04
Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF) Eur J Cancer (1993) 1.01
Interleukin-4 induces secretion of CSF for granulocytes and CSF for macrophages by peripheral blood monocytes. Blood (1989) 1.01
Interleukin-12 secretion by Mycobacterium tuberculosis-infected macrophages. Infect Immun (1997) 1.01
Human interleukin 2: molecular biology, physiology and clinical possibilities. Immunobiology (1986) 1.00
BCL-2 induction is part of the strategy of Epstein-Barr virus. Leuk Lymphoma (1994) 1.00
Direct effects of phosphorylation on the preferred backbone conformation of peptides: a nuclear magnetic resonance study. Biophys J (1999) 0.99
Retracted Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest (1989) 0.99
The acute monocytic leukemias: multidisciplinary studies in 45 patients. Medicine (Baltimore) (1980) 0.99
Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother (1999) 0.99
The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leuk Lymphoma (1998) 0.99
Design and validation of a partial-genome microarray for transcriptional profiling of the Bradyrhizobium japonicum symbiotic gene region. Mol Genet Genomics (2005) 0.98
Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer (1991) 0.98
Exocytosis requires asymmetry in the central layer of the SNARE complex. EMBO J (2000) 0.98
Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood (1990) 0.97
Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood (1997) 0.97
Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Ann Hematol (2003) 0.97
Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol (1997) 0.97
Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. J Immunol (1989) 0.97
Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol (1995) 0.97
Leukotriene B4 transcriptionally activates interleukin-6 expression involving NK-chi B and NF-IL6. Eur J Immunol (1992) 0.96
Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J Immunol (1983) 0.96
High concentrations of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet (1992) 0.95
Characterization of malignant lymphomas in leukemic phase by multiple differentiation markers of mononuclear cells. Correlations with clinical features and conventional morphology. Am J Med (1977) 0.95
Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res (1992) 0.95
Aspergillus Peritonitis complicating perforated appendicitis in adult acute leukemia. J Surg Oncol (1982) 0.94
Retracted Interleukin 1 stimulates T lymphocytes to produce granulocyte-monocyte colony-stimulating factor. J Clin Invest (1988) 0.94